Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
FT-819 by Fate Therapeutics for Systemic Lupus Erythematosus: Likelihood of Approval
FT-819 is under clinical development by Fate Therapeutics and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData,...
FT-819 by Fate Therapeutics for Non-Hodgkin Lymphoma: Likelihood of Approval
FT-819 is under clinical development by Fate Therapeutics and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase...
FT-819 by Fate Therapeutics for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
FT-819 is under clinical development by Fate Therapeutics and currently in Phase I for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute...
Risk adjusted net present value: What is the current valuation of Fate Therapeutics's FT-819?
FT-819 is a gene-modified cell therapy commercialized by Fate Therapeutics, with a leading Phase I program in B-Cell Acute Lymphocytic...
FT-819 by Fate Therapeutics for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
FT-819 is under clinical development by Fate Therapeutics and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL). According...